Atx-101, a cell-penetrating protein targeting pcna, can be safely administered as intravenous infusion in patients and shows clinical activity in a phase 1 study

HIGHLIGHTS

• who: Charlotte Rose Lemech from the (UNIVERSITY) have published the paper: ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study, in the Journal: (JOURNAL) of 23/Dec/2022
• what: The authors report results of the ATX-101 first-in-human study in patients with advanced solid tumors. If, after 6 weeks, no tumor progression was measured, treatment could be continued in a second, longterm follow-up study until disease progression or unacceptable toxicity with the primary objective safety . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.